Takeda Pharmaceutical Co Ltd ADR
Quarterly Financials
| Values in thousands | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
|---|---|---|---|---|
Revenue | $1,176,038,000 | $1,207,990,000 | $1,207,990,000 | $1,111,186,000 |
Gross Profit | 781,727,000 | 658,205,000 | 658,205,000 | 731,705,000 |
EBITDA | 380,278,000 | 411,932,000 | 384,548,000 | 291,975,000 |
EBIT | 187,826,000 | 219,712,000 | 192,328,000 | 104,914,000 |
Net Income | 92,046,000 | 95,248,000 | 95,248,000 | 105,720,000 |
Net Change In Cash | 1,176,038,000 | 1,207,990,000 | 1,207,990,000 | 1,111,186,000 |
Free Cash Flow | 188,511,000 | 32,506,000 | 21,577,000 | 69,327,000 |
Cash | 859,015,000 | 804,272,000 | 804,272,000 | 288,359,000 |
Basic Shares | 3,166,357 | 1,569,082 | 1,589,055 | 1,585,118 |
Annual Financials
| Values in thousands | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 |
|---|---|---|---|---|
Revenue | $4,263,762,000 | $4,027,478,000 | $3,569,006,000 | $3,197,812,000 |
Gross Profit | 2,832,257,000 | 2,783,406,000 | 2,462,160,000 | 2,203,504,000 |
EBITDA | 900,328,000 | 1,156,463,000 | 1,183,213,000 | 983,718,000 |
EBIT | 172,326,000 | 492,063,000 | 600,062,000 | 424,047,000 |
Net Income | 144,067,000 | 317,017,000 | 230,059,000 | 376,005,000 |
Net Change In Cash | 4,263,762,000 | 4,027,478,000 | 3,569,006,000 | 3,197,812,000 |
Free Cash Flow | 235,614,000 | 343,467,000 | 937,068,000 | 774,463,000 |
Cash | 457,800,000 | 533,530,000 | 849,695,000 | 966,222,000 |
Basic Shares | 1,580,343 | 1,569,872 | 1,577,169 | 1,573,537 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-09-30 | $29.07 |
2024-06-30 | $0.19 |
2024-03-31 | -$0.006 |
2023-12-31 | $33.79 |
